Genital Psoriasis

Genital psoriasis typically presents as well-defined, bright red, smooth patches of skin with minimal or no scale due to local moisture.

Common symptoms include:

• Persistent itching, sometimes severe
• Soreness, burning, or stinging sensation
• Increased sensitivity of the affected skin
• Fissuring (cracks), which may cause pain during movement or intercourse

Lesions most often affect the groin folds, vulva, penis, scrotum, or perianal area.

Genital psoriasis often appears different from psoriasis elsewhere due to the moist environment of the area.

It typically presents as well-demarcated, bright red, smooth, and shiny patches with minimal or absent scaling. The skin may appear inflamed and slightly raised.

Commonly affected areas include the groin, inner thighs, vulva, penis, scrotum, and perianal region. Fissures or small cracks may be present and can be painful.

Genital psoriasis can develop at any age but most commonly begins in early adulthood, often alongside or after psoriasis affecting other areas of the body.

In some individuals, the genital area may be the first or only site affected. Symptoms may appear gradually or flare intermittently, often triggered by factors such as friction, infections, stress, or certain medications.

The condition typically follows a relapsing–remitting pattern, with periods of improvement and flare-ups over time.

Untreated genital psoriasis may lead to both physical and psychological complications.

Persistent inflammation can result in fissuring, causing pain and increasing susceptibility to secondary infections, particularly fungal infections in this moist area.

Symptoms may significantly impact sexual function and intimacy due to discomfort or pain.

As part of a systemic inflammatory condition, psoriasis is associated with comorbidities such as psoriatic arthritis and, less commonly, metabolic or cardiovascular disease.

Appropriate management helps reduce symptoms, minimise complications, and improve quality of life.

Genital psoriasis is an immune-mediated inflammatory condition and is not infectious or sexually transmitted.

It results from dysregulation of the immune system, leading to accelerated skin cell turnover and local inflammation. Genetic susceptibility plays a key role, with many patients having a family history of psoriasis.

Environmental and local factors contribute to disease expression, particularly in the genital area. Common triggers include friction (Koebner phenomenon), sweating, irritation, infections, and psychological stress.

Risk factors for developing psoriasis, including genital involvement, include:

• Family history of psoriasis
• Genetic predisposition
• Obesity (increased skin folds and friction)
• Smoking and excess alcohol intake
• Certain medications (e.g. lithium, beta-blockers, antimalarials)
• Infections or systemic illness

Genital involvement may occur in isolation or as part of more widespread psoriasis.

Severity and flare frequency may be increased by:

• Ongoing friction (tight clothing, sexual activity)
• Moisture and occlusion in skin folds
• Irritants (soaps, wipes, topical products)
• Secondary infection, particularly candidiasis
• Psychological stress
• Smoking and excess alcohol use

Repeated mechanical irritation (Koebner phenomenon) is a key factor in persistent or worsening genital disease.

Yes. Genital psoriasis is not related to sexual transmission, so condom use does not affect whether it develops.

However, friction during sexual activity — even with condom use — may trigger or worsen symptoms in some individuals.

No. Genital psoriasis is not infectious and cannot be passed between people.

It develops due to a combination of genetic predisposition and immune system factors, often influenced by triggers such as stress, illness, or skin irritation.

Genital psoriasis cannot be fully prevented, as it is driven by genetic and immune factors.

However, flare-ups may be reduced by:

• Minimising friction and irritation
• Using gentle, non-irritating skin care
• Keeping the area dry but well moisturised
• Managing stress and general health
• Avoiding known personal triggers

Early recognition and appropriate treatment are key to maintaining control of symptoms.

Genital psoriasis is primarily a clinical diagnosis based on history and examination.

Typical findings include well-demarcated, bright red, smooth patches with minimal scale due to local moisture. A clinician will also assess for psoriasis elsewhere (e.g. scalp, elbows, knees, nails) and ask about personal or family history.

Because several conditions can mimic genital psoriasis, targeted investigations (e.g. fungal swabs or scrapings) may be used to exclude infection.

Skin biopsy is rarely required but may be considered if the presentation is atypical or diagnosis remains uncertain.

Accurate diagnosis relies on a combination of:

• Characteristic clinical appearance in the genital area
• Evidence of psoriasis at other body sites or nail involvement
• Personal or family history of psoriasis
• Response to previous treatments

Excluding common mimics — particularly candidiasis, dermatophyte infection, contact dermatitis, and lichen sclerosus — is essential, as management differs significantly.

Yes. Genital psoriasis is frequently misdiagnosed because its appearance differs from classic psoriasis.

Common differentials include:

• Candidiasis (thrush)
• Dermatophyte infection (tinea cruris)
• Irritant or allergic contact dermatitis
• Lichen sclerosus or lichen planus

Distinguishing these conditions is important, as inappropriate treatment (e.g. topical steroids in unrecognised fungal infection) may worsen symptoms.

Diagnosis is usually clinical.

When uncertainty exists, additional tests may include:

• Fungal swabs or skin scrapings
• Bacterial swabs if secondary infection is suspected
• Skin biopsy in atypical or treatment-resistant cases

These investigations are used to exclude alternative diagnoses rather than confirm psoriasis directly.

No. Genital psoriasis is not infectious and cannot be transmitted through sexual contact.

There is no medical requirement to inform a partner. However, some people choose to share this information to avoid misunderstanding and to support comfort and communication during intimacy.

Treatment reduces inflammation and symptoms such as itching, pain, and irritation, improving daily comfort and function.

It also helps prevent fissuring and secondary infection, particularly in this high-friction, moist environment.

Effective management can significantly improve quality of life, including sexual wellbeing, and reduce the frequency and severity of flare-ups.

No. Genital psoriasis is an inflammatory condition and is not treated surgically.

Management is primarily medical. In moderate to severe or refractory cases, systemic treatments (e.g. oral or biologic therapies) may be considered under specialist care, but surgery has no role.

Yes. Supportive skin care is an essential part of management.

Helpful measures include:

• Regular use of emollients as moisturisers and soap substitutes
• Avoiding fragranced or irritant products
• Minimising friction (loose clothing, appropriate lubrication during sexual activity)
• Gently drying the area after washing

Over-the-counter psoriasis treatments designed for thicker skin (e.g. scalp, elbows) should be avoided unless advised, as they may cause irritation.

Most people can be treated, but management depends on accurate diagnosis and individual factors.

Key considerations include:

• Excluding infections (e.g. candidiasis, STIs), which may require treatment first
• Pregnancy or breastfeeding, where some treatments are limited
• Previous or inappropriate topical treatment altering the clinical appearance
• Co-existing skin conditions or medication use affecting treatment choice

Treatment is usually tailored to balance safety, tolerability, and effectiveness.

Genital psoriasis is a chronic, relapsing condition requiring long-term management rather than cure.

Prognosis is generally good, with most patients achieving effective symptom control using appropriate treatment. The condition typically follows a relapsing–remitting course, with periods of clearance and flare-ups.

Genital involvement can be more sensitive and prone to recurrence due to friction and local irritation. While disease activity may fluctuate over time, sustained control is achievable with appropriate therapy and trigger management.

Psoriasis is a systemic inflammatory condition and, in some individuals, may be associated with comorbidities such as psoriatic arthritis.

No. Genital psoriasis is not a sexually transmitted infection and cannot be passed to a partner through sexual contact or physical touch.

Because it is not contagious, there is no medical requirement to inform a partner.

However, some people choose to discuss it so their partner understands the condition, especially if there is visible redness or irritation. This can sometimes make intimacy more comfortable and reduce misunderstandings.

Genital psoriasis does not usually affect fertility, pregnancy outcomes, or mode of delivery.

Disease activity may change during pregnancy — some individuals experience improvement, while others may have no change or worsening. Flare-ups are more common in the postpartum period.

The main consideration is treatment selection, as some topical and systemic therapies are not suitable during pregnancy or breastfeeding. Management should be adjusted accordingly.

Genital psoriasis alone is not an indication for caesarean section, and vaginal delivery is usually appropriate.

No. Psoriasis is a long-term autoimmune condition, so it is not possible to become immune to it.

Many people experience periods where their skin becomes clear, known as remission, but symptoms can return later. Flare-ups may be triggered by factors such as stress, certain medications, infections, or friction in the genital area.

Long-term management focuses on controlling symptoms and reducing the frequency of flare-ups.

Genital psoriasis cannot be prevented, but recurrence and flare frequency can be reduced.

Key measures include:

• Minimising friction and moisture in the genital area
• Regular use of emollients to support the skin barrier
• Avoiding irritants (e.g. fragranced products, harsh cleansers)
• Identifying and managing individual triggers (e.g. stress, infections, medications)

Long-term control depends on consistent skin care and appropriate use of prescribed treatments.

No. Genital psoriasis cannot be passed to a baby during pregnancy or childbirth.

It is not an infection and is not contagious. The condition is caused by inflammation related to the immune system, not by bacteria or viruses.

Psoriasis can have a genetic component, which means a child may have a higher chance of developing psoriasis later in life if it runs in the family. However, this is different from passing an infection during pregnancy or delivery.

Genital psoriasis itself does not usually affect fertility or fetal development.

However, psoriasis is a systemic inflammatory condition, and moderate to severe disease (not specific to genital involvement) has been associated with a small increased risk of adverse pregnancy outcomes, such as preterm birth or low birth weight.

Local symptoms may be more noticeable due to increased vascularity, moisture, and sensitivity during pregnancy.

The main clinical consideration is treatment safety, as some topical and systemic therapies are contraindicated or require modification during pregnancy.

Genital involvement is common in psoriasis, affecting up to 30–60% of individuals at some point.

Pregnancy does not specifically increase the incidence of genital psoriasis, but hormonal and immunological changes may alter disease activity. Many individuals experience improvement during pregnancy, while others have no change or worsening.

Data specifically on isolated genital psoriasis in pregnancy are limited.

Management focuses on symptom control using treatments with established safety profiles.

Common options include:

• Emollients as first-line therapy
• Low-potency topical corticosteroids used sparingly
• Topical calcineurin inhibitors (may be considered, although data in pregnancy are limited and specialist guidance is advised)

Certain treatments are contraindicated, including methotrexate, acitretin, and some systemic immunosuppressants.

Due to increased absorption in genital skin, treatments should be used at the lowest effective potency and duration.

Psoriasis itself usually does not pose a direct risk to pregnancy, but careful management can help reduce discomfort and flare-ups.

Helpful precautions include:

• Using fragrance-free moisturisers or emollients regularly
• Avoiding scented soaps, bubble baths, or harsh cleansers
• Wearing loose, breathable clothing to reduce friction and heat
• Keeping the skin clean and gently drying the area after washing

Hormonal changes during pregnancy may cause symptoms to improve or flare, so monitoring skin changes and adjusting treatment if needed can help maintain comfort.

Genital psoriasis does not affect breastfeeding or breast milk quality.

However, flare-ups are common in the postpartum period due to hormonal changes and physical stress.

Treatment may need adjustment during breastfeeding. If psoriasis affects the breast or nipple, topical treatments should be used cautiously to avoid infant exposure.

With appropriate management, postpartum recovery and breastfeeding are usually unaffected.

Yes. Genital psoriasis can be effectively managed, although it is a chronic relapsing condition.

Treatment aims to reduce inflammation, control symptoms, and maintain skin integrity. Due to the sensitivity of genital skin, therapies must be carefully selected.

First-line treatments include:

• Low- to moderate-potency topical corticosteroids (used intermittently)
• Topical calcineurin inhibitors (e.g. tacrolimus, pimecrolimus), particularly for longer-term use
• Emollients to support the skin barrier

Vitamin D analogues may be used cautiously but are often less well tolerated in the genital area due to irritation.